Methodological Evaluation of Bias in Randomized Clinical Trials

Randomised clinical trials underpin evidence‐based medicine by comparing interventions under controlled conditions. Methodological rigour is crucial to ensure that estimated treatment effects reflect true efficacy and safety rather than artefacts of trial design or conduct. Key sources of systematic error include inadequacies in randomisation, lack of allocation concealment and absence of blinding, each capable of exaggerating or attenuating observed outcomes. Meta-epidemiological studies have systematically examined how these features influence effect estimates, revealing that shortcomings in core domains can lead to overestimation of benefits, underestimation of harms and increased heterogeneity across trials. The evolution of risk-of-bias tools has standardised assessment, yet challenges persist in implementation consistency and interpretation. Emerging approaches harness artificial intelligence to streamline evaluations, while ongoing refinements to bias frameworks aim to balance methodological stringency with practicality, thereby enhancing the credibility and applicability of trial findings in clinical and policy decision-making worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Methodological Evaluation of Bias in Randomized Clinical Trials publication trend

The graph below shows the total number of articles in methodological evaluation of bias in randomized clinical trials across all publications each year (not limited to Nature Index journals).

Technical terms

Randomisation: Allocation of participants by chance to treatment groups to prevent selection bias.

Allocation concealment: Technique ensuring that investigators cannot predict or influence upcoming assignments during participant enrolment.

Blinding: Masking participants, healthcare providers or outcome assessors to allocated interventions to reduce performance and detection bias.

Risk-of-bias tool: Structured framework for appraising potential sources of systematic error in trial design and conduct.

Meta-epidemiological study: Research approach that evaluates methodological features across collections of trials or meta-analyses to quantify their influence on effect estimates.

References

1. Influence of lack of blinding on the estimation of medication-related harms: a retrospective cohort study of randomized controlled trials. BMC Medicine (2024).
2. Large Language Model–Assisted Risk-of-Bias Assessment in Randomized Controlled Trials Using the Revised Risk-of-Bias Tool: Evaluation Study. Journal of Medical Internet Research (2025).
3. Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies. PLOS ONE (2016).
4. Evaluation of the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Systematic Reviews (2014).
5. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Systematic Reviews (2016).